Fernanda M P Rodrigues1,2, Robin Marlow3, Maria João Simões4, Leon Danon5,6, Shamez Ladhani7,8, Adam Finn3. 1. Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. 2. Faculty of Medicine, University of Coimbra, Coimbra, Portugal. 3. Bristol Children's Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom. 4. Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal. 5. Department of Computer Science, University of Exeter, Exeter, United Kingdom. 6. The Alan Turing Institute, British Library, London, United Kingdom. 7. Paediatric Infectious Diseases Research Group, St George's, University of London, London, United Kingdom. 8. Immunisation and Countermeasures Division, Public Health England, London, United Kingdom.
Abstract
Importance: A 4-component meningococcus group B vaccine (4CMenB) is the only vaccine in use to prevent group B invasive meningococcal disease in young children, but no matched controlled studies have evaluated it. Objective: To determine the association between receipt of 4CMenB and invasive group B meningococcal disease. Design, Setting, and Participants: Matched incidence density case-control study. Patients presenting from October 2014 to March 2019 were ascertained, with follow-up until death or discharge (last follow-up in June 2019) in 31 pediatric services in Portugal. Children and adolescent residents in Portugal with laboratory-confirmed invasive meningococcal disease were included. Controls, usually 2 per case, with unrelated conditions who were at the same hospital at the same time were matched for sex, age, and residence. Exposures: Immunization with 4CMenB, ascertained from the national database (2-4 doses are recommended, depending on age). Main Outcomes and Measures: The primary outcome was group B invasive meningococcal disease in fully vaccinated cases compared with controls. The secondary outcomes were all serogroup invasive meningococcal disease in fully vaccinated cases compared with controls and group B and all serogroup invasive meningococcal disease in cases compared with controls who received at least 1 vaccine dose. Results: Of 117 patients with invasive meningococcal disease, 98 were eligible for inclusion and 82 had group B invasive meningococcal disease; 69 were old enough to have been fully vaccinated and considered protected. Among these 69 cases, the median (interquartile range) age was 24 (4.5-196) months, 42 were male, and the median (interquartile range) duration of hospitalization was 8 (0-86) days. Five of 69 cases (7.2%) and 33 of 142 controls (23.1%) were fully vaccinated (difference, -16.0% [95% CI, -26.3% to -5.7%]; odds ratio [OR], 0.21 [95% CI, 0.08-0.55]). For all serogroup invasive meningococcal disease, 6 of 85 cases (7.1%) and 39 of 175 controls (22.3%) were fully vaccinated (difference, -15.2% [95% CI, -24.3% to -6.1%]; OR, 0.22 [95% CI, 0.09-0.53]). For group B disease, 8 of 82 cases (9.8%) and 50 of 168 controls (29.8%) received at least 1 vaccine dose (difference, -20.0% [95% CI, -30.3% to -9.7%]; OR, 0.18 [95% CI, 0.08-0.44]) and for all serogroup invasive meningococcal disease, 11 of 98 cases (11.2%) and 61 of 201 controls (30.3%) received at least 1 vaccine dose (difference, -19.1% [95% CI, -28.8% to -9.5%]; OR, 0.23 [95% CI, 0.11-0.49]). Conclusions and Relevance: During the first 5 years of vaccine availability in Portugal, vaccination with 4CMenB was less likely among children who developed invasive meningococcal disease compared with matched controls without invasive meningococcal disease. These findings may help inform the use of the 4CMenB vaccine in clinical practice. Trial Registration: ISRCTN Identifier: ISRCTN10901628.
Importance: A 4-component meningococcus group B vaccine (4CMenB) is the only vaccine in use to prevent group B invasive meningococcal disease in young children, but no matched controlled studies have evaluated it. Objective: To determine the association between receipt of 4CMenB and invasive group B meningococcal disease. Design, Setting, and Participants: Matched incidence density case-control study. Patients presenting from October 2014 to March 2019 were ascertained, with follow-up until death or discharge (last follow-up in June 2019) in 31 pediatric services in Portugal. Children and adolescent residents in Portugal with laboratory-confirmed invasive meningococcal disease were included. Controls, usually 2 per case, with unrelated conditions who were at the same hospital at the same time were matched for sex, age, and residence. Exposures: Immunization with 4CMenB, ascertained from the national database (2-4 doses are recommended, depending on age). Main Outcomes and Measures: The primary outcome was group B invasive meningococcal disease in fully vaccinated cases compared with controls. The secondary outcomes were all serogroup invasive meningococcal disease in fully vaccinated cases compared with controls and group B and all serogroup invasive meningococcal disease in cases compared with controls who received at least 1 vaccine dose. Results: Of 117 patients with invasive meningococcal disease, 98 were eligible for inclusion and 82 had group B invasive meningococcal disease; 69 were old enough to have been fully vaccinated and considered protected. Among these 69 cases, the median (interquartile range) age was 24 (4.5-196) months, 42 were male, and the median (interquartile range) duration of hospitalization was 8 (0-86) days. Five of 69 cases (7.2%) and 33 of 142 controls (23.1%) were fully vaccinated (difference, -16.0% [95% CI, -26.3% to -5.7%]; odds ratio [OR], 0.21 [95% CI, 0.08-0.55]). For all serogroup invasive meningococcal disease, 6 of 85 cases (7.1%) and 39 of 175 controls (22.3%) were fully vaccinated (difference, -15.2% [95% CI, -24.3% to -6.1%]; OR, 0.22 [95% CI, 0.09-0.53]). For group B disease, 8 of 82 cases (9.8%) and 50 of 168 controls (29.8%) received at least 1 vaccine dose (difference, -20.0% [95% CI, -30.3% to -9.7%]; OR, 0.18 [95% CI, 0.08-0.44]) and for all serogroup invasive meningococcal disease, 11 of 98 cases (11.2%) and 61 of 201 controls (30.3%) received at least 1 vaccine dose (difference, -19.1% [95% CI, -28.8% to -9.5%]; OR, 0.23 [95% CI, 0.11-0.49]). Conclusions and Relevance: During the first 5 years of vaccine availability in Portugal, vaccination with 4CMenB was less likely among children who developed invasive meningococcal disease compared with matched controls without invasive meningococcal disease. These findings may help inform the use of the 4CMenB vaccine in clinical practice. Trial Registration: ISRCTN Identifier: ISRCTN10901628.
Authors: Jessica R MacNeil; Nancy Bennett; Monica M Farley; Lee H Harrison; Ruth Lynfield; Megin Nichols; Sue Petit; Arthur Reingold; William Schaffner; Ann Thomas; Tracy Pondo; Leonard W Mayer; Thomas A Clark; Amanda C Cohn Journal: Pediatrics Date: 2015-01-12 Impact factor: 7.124
Authors: Manish Sadarangani; Tim Sell; Mildred A Iro; Matthew D Snape; Merryn Voysey; Adam Finn; Paul T Heath; Gianni Bona; Susanna Esposito; Javier Diez-Domingo; Roman Prymula; Adefowope Odueyungbo; Daniela Toneatto; Andrew J Pollard Journal: CMAJ Date: 2017-10-16 Impact factor: 8.262
Authors: Sydel R Parikh; Nick J Andrews; Kazim Beebeejaun; Helen Campbell; Sonia Ribeiro; Charlotte Ward; Joanne M White; Ray Borrow; Mary E Ramsay; Shamez N Ladhani Journal: Lancet Date: 2016-10-27 Impact factor: 79.321
Authors: Shamez N Ladhani; Nick Andrews; Sydel R Parikh; Helen Campbell; Joanne White; Michael Edelstein; Xilian Bai; Jay Lucidarme; Ray Borrow; Mary E Ramsay Journal: N Engl J Med Date: 2020-01-23 Impact factor: 91.245
Authors: Alessandro Muzzi; Alessandro Brozzi; Laura Serino; Margherita Bodini; Raquel Abad; Dominique Caugant; Maurizio Comanducci; Ana Paula Lemos; Maria Cecilia Gorla; Pavla Křížová; Claudia Mikula; Robert Mulhall; Michael Nissen; Hanna Nohynek; Maria João Simões; Anna Skoczyńska; Paola Stefanelli; Muhamed-Kheir Taha; Maija Toropainen; Georgina Tzanakaki; Kumaran Vadivelu-Pechai; Philip Watson; Julio A Vazquez; Gowrisankar Rajam; Rino Rappuoli; Ray Borrow; Duccio Medini Journal: Vaccine Date: 2019-01-17 Impact factor: 3.641
Authors: Michelle C Stanton; David Taylor-Robinson; David Harris; Fauzia Paize; Nick Makwana; Scott J Hackett; Paul B Baines; F Andrew I Riordan; Omnia Marzouk; Alistair P J Thomson; Peter J Diggle; C Anthony Hart; Enitan D Carrol Journal: PLoS One Date: 2011-10-07 Impact factor: 3.240
Authors: Makda S Gebre; Luis A Brito; Lisa H Tostanoski; Darin K Edwards; Andrea Carfi; Dan H Barouch Journal: Cell Date: 2021-03-18 Impact factor: 41.582